Drugs /

ltt462

Back to Drugs List
Associated Genetic Biomarkers

Overview

NCI Definition [1]:
An orally available inhibitor of extracellular signal-regulated kinase (ERK), with potential antineoplastic activity. Upon oral administration, LTT462 binds to and inhibits ERK, thereby preventing the activation of ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The mitogen-activated protein kinase (MAPK)/ERK pathway is upregulated in numerous tumor cell types and plays a key role in tumor cell proliferation, differentiation and survival.

Clinical Trials

View Clinical Trials for ltt462

Ltt462 has been investigated in 4 clinical trials, of which 4 are open and 0 are closed. Of the trials investigating ltt462, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open).

BRAF Codon 600 Missense, NRAS Mutation, and BRAF Mutation are the most frequent biomarker inclusion criteria for ltt462 clinical trials.

Cutaneous melanoma, colorectal carcinoma, and myelofibrosis are the most common diseases being investigated in ltt462 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Ltt462
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating ltt462 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
ltt 462, erk inhibitor ltt462
Drug Categories [2]:
ERK inhibitor, Serine/threonine kinase inhibitors
Drug Target(s) [2]:
MAPK1, MAPK3, MAPK6, MAPK7
NCIT ID [1]:
C126687

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.